|Bid||20.00 x 900|
|Ask||29.50 x 1000|
|Day's Range||26.34 - 27.41|
|52 Week Range||16.21 - 52.43|
|Beta (5Y Monthly)||1.50|
|PE Ratio (TTM)||3.33|
|Earnings Date||Aug 10, 2022 - Aug 15, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||47.25|
Subscribe to Yahoo Finance Plus to view Fair Value for ITOS
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 02, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will participate in a panel discussion at the upcoming 2022 Wedbush PacGrow Healthcare Conference titled: “IOs Wide Open – Opportunities and Challenges i
The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. Many biotech companies have shifted their focus entirely or added COVID-19 vaccines and treatments to their product pipeline. Early-stage biotech companies are prone to wild swings in revenue due to going from nearly no revenue to having a significant revenue stream once a drug is approved or a partnership with another company is reached.
With its stock down 38% over the past three months, it is easy to disregard iTeos Therapeutics (NASDAQ:ITOS). But if...